In the high-stakes world of clinical trials, choosing between fragmented point solutions and a unified clinical research software can make or break your study’s success. The Pitfalls of Fragmented Point
With the recent advances in AI and digital health, there is no doubt clinical trials are experiencing a paradigm shift. As new therapies emerge to address complex diseases such as
Clinical trials drive medical advancements, with thousands conducted globally each year. Did you know? The average clinical trial can take 7 to 10 years. Yet, the success of these studies
Meanwhile, the clinical trial industry is making enormous efforts to drive qualitative outcomes. Efficient data collection and patient engagement are more necessary than ever. This is where eCOA (electronic Clinical
Imagine you’re a clinical trial manager overseeing multiple trial sites across different countries. You’re juggling participant recruitment, ensuring regulatory compliance, managing study data, coordinating site visits, and constantly communicating with
Just imagine you’re running a multi-site clinical trial across continents. Lives are on the line, researchers are drowning in data, and sponsors are pushing for faster results. Every misstep—a delayed
The exciting rise of decentralized clinical trials (DCTs) has sparked interest and enthusiasm in the medical research community. These trials are changing the way medical research is done! Unlike traditional
Source: American Pharmaceutical Review Gene therapies stand at the forefront of medical breakthroughs, promising revolutionary treatment possibilities. These therapies involve manipulating or modifying genes to treat or prevent diseases, presenting
Source: Patient Worthy Challenges Unique to Cell and Gene Therapies (CGTx) Clinical Trials Cell and gene therapies (CGTx) have emerged as a novel and advanced treatment modality with a one-and-done
Source: Healthcare Business Today Cell and gene therapies (CGTx) hold immense promise as transformative treatments for a wide range of diseases. However, the successful translation of these therapies from the
Source– BioProcess International The infusion of artificial intelligence (AI) technology in drug development has led to transformative solutions to age-old challenges, reshaping the trajectory from laboratory discovery to market availability.
Delays in clinical trials, worsened by the Inflation Reduction Act (IRA), are now a challenge to patient access to new therapies. Evolving complex regulatory requirements, patient recruitment issues, and logistical
Jeeva Clinical Trials Inc.